Treatment

Treatment is by intramuscular (IM) or subcutaneous (SC) injection of the GcMAF-Forte macrophage activating factor, administered once a week, or as prescribed by the treating physician. Proper aseptic handling is essential when using the vials to ensure safety and maintain the integrity of the therapy. The process of administering GcMAF-Forte requires careful attention to cleanliness and sterile techniques to avoid contamination and ensure the treatment’s effectiveness. It is essential that all healthcare providers involved are trained in the appropriate administration techniques.

Dosing Recommendations for GcMAF-Forte

The dosage and frequency of GcMAF-Forte administration are determined at the discretion of the treating physician based on the individual needs of the patient. The flexibility of the treatment plan allows it to be customized to the severity of the disease and the patient’s response. No upper limit has been established for GcMAF-Forte, which provides flexibility in the dosage depending on the patient’s condition, making this treatment adaptable and responsive to each patient’s needs.

Cancer, HIV/AIDS, Hepatitis, Tuberculosis

For patients dealing with cancer, HIV/AIDS, hepatitis, and tuberculosis, it is recommended to administer high-dose GcMAF-Forte once a week. For the maximum effect, we suggest 2 ml once weekly, although the precise dosage may vary depending on the severity of the disease and the patient’s overall health condition.

One typical course of high-dose GcMAF-Forte consists of 10 doses over 10 weeks. Depending on the progress of the disease, additional courses may be required to achieve the desired therapeutic effects. For some patients, particularly those with advanced conditions or more severe symptoms, the physician may recommend a longer course of treatment.

Macrophage activation is crucial for the immune system’s effective functioning, and GcMAF-Forte therapy is designed to provide this necessary boost. It is important that GcMAF-Forte therapy continues as long as the disease is present, with a period of follow-up therapy afterward to reduce the chances of recurrence and ensure sustained immune support.

Improvements in symptoms should typically be observed within 2 months, though individual responses may vary. The minimum treatment course is 10 weeks, but each patient’s progress is unique, and additional courses may be necessary depending on how the patient is responding to treatment. In some cases, long-term maintenance doses of GcMAF-Forte therapy may be required to help patients stay symptom-free and ensure that their immune system remains capable of handling future challenges.

Note that these dosage recommendations apply only to IMMI GcMAF-Forte.

Autism Spectrum Disorders (ASD)

For individuals with Autism Spectrum Disorders (ASD), the recommended treatment involves 2 ml of High-Dose GcMAF-Forte, administered once weekly by subcutaneous injection. This therapy is designed to improve immune function and, over time, has been shown to help with the symptoms associated with ASD.

Some improvements in symptoms should be observed within the first 2 months of therapy. As with other conditions, the minimum treatment course for ASD is 10 weeks, but each individual’s needs vary, and additional courses may be necessary depending on their response to treatment. For many patients, long-term maintenance doses of GcMAF-Forte therapy are recommended to keep the immune system functioning optimally and to prevent the return of symptoms. Once the immune system has been sufficiently supported, it is crucial to continue therapy until the body has fully recovered and is capable of handling any future challenges on its own.

For Autism Spectrum Disorders, we recommend consulting for a special therapy plan tailored to the needs of each individual patient.

Note that these dosage recommendations apply only to IMMI GcMAF-Forte.

Get started with GcMAF-Forte therapy and take the first step toward a stronger, healthier immune system by consulting with our specialists.